Managing ADHD Treatment During Stimulant Supply Shortages
The 2022-2024 methylphenidate/amphetamine shortages created a genuine substitution dilemma under real supply constraint — not a hypothetical access question, but a documented, structural, ongoing problem.
R.N. has a spreadsheet now, which is its own kind of irony she points out before anyone else can: a woman of 27 whose executive-function deficits are the entire reason she's in this office has built a six-column tracking system of which pharmacies in a fifteen-mile radius have filled her prescription in the past four months, on what date, and how many days she went without medication between fills. She works in accounts payable, and has managed ADHD on the same mixed amphetamine salts formulation for six years without incident until this past year, when what used to be a routine monthly pickup became a genuine logistical project. Three of the last five months, her regular pharmacy has had no stock at all; twice she has driven to a pharmacy forty minutes away after a phone-tree search, only to arrive and find the quantity they quoted that morning had already been claimed by someone else.
The gaps between fills, real days without any medication rather than a planned drug holiday, have started showing up in her work performance review, and she is here today not to relitigate her diagnosis or her treatment's effectiveness — both are well established — but to build a plan that doesn't depend on a national supply chain she has no control over and, increasingly, no ability to reliably predict.
The spreadsheet itself is worth a closer look, because it tells a more specific story than "the medication is sometimes unavailable." The gaps cluster unpredictably rather than following any seasonal or monthly pattern she's been able to identify, which is part of what makes advance planning so difficult — a shortage that reliably hit the first week of every month could at least be worked around, but hers has run anywhere from three days early to eleven days late relative to her refill date, with no warning from the pharmacy until she calls or shows up. Her most recent gap ran six full days, during which her manager specifically noted in a written review that two client deliverables were late, the first negative feedback of her six-year employment history at that company.
Building a plan around an unpredictable national shortage, not just a prescription refill
The shortage itself is worth naming specifically rather than treated as vague bad luck: the FDA first listed amphetamine mixed salts as being in shortage in October 2022, driven substantially by a DEA production-quota system under which manufacturers used only about seventy percent of their allotted 2022 quota, a roughly one-billion-dose shortfall nationally. That shortage later extended to methylphenidate extended-release formulations too, added to the FDA list in mid-2023. This isn't a manufacturing glitch that's about to resolve on its own — it's a structural, multi-year problem, and her plan should be built assuming it continues, not assuming next month is the exception.
Given that framing, I'd rather not simply switch her to a different amphetamine salt formulation, since the shortage has hit multiple manufacturers within that same drug class fairly broadly — she could just as easily find herself back in the same position with a different product name. Methylphenidate, a genuinely different molecule with its own separate manufacturing and supply chain, gives her real insurance against a shortage that's specifically hit amphetamine products hardest, even though it means a real medication change after six stable years on something that worked.
I'd want to weigh that against the real cost of switching something that's worked for six years without incident — a class switch isn't risk-free either, and if her current medication becomes available again next month, she may have traded a supply problem for an efficacy or tolerability one.
Both concerns can be addressed without fully committing either way today: keep her current prescription active as primary, but add a standing backup prescription for a methylphenidate product on file at a second pharmacy, filled only if the primary fill fails that month. That gives her a real, usable safety net without asking her to abandon a medication that has worked for six years on the chance the shortage might hit it again.
Agreed: current medication continued as primary, backup methylphenidate prescription and second pharmacy established as a standing safety net rather than switching her proactively off a medication that has worked for six years.
The psychiatrist's underlying discomfort with building a plan around a national shortage that might resolve, rather than around her own clinical picture, was acknowledged directly — both physicians agreed the plan was a reasonable practical response to a real, ongoing structural problem, not their preferred baseline for how this decision should ideally be made.